Search This Blog

Wednesday, August 28, 2019

Ascendis Pharma reports Q2 results

Ascendis Pharma (NASDAQ:ASND): Q2 GAAP EPS of -€1.25.
Revenue of €3.21M (+15950.0% Y/Y).
Cash and equivalents of €690.4M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)